newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

  • Aligos Therapeutics received a $25M upfront payment from Xiamen Amoytop Biotech Co., Ltd. for the exclusive license of pevifoscorvir sodium in Greater China.
  • Pevifoscorvir sodium was granted Breakthrough Therapy Designation by China's National Medical Products Administration (NMPA) Center for Drug Evaluation.
  • Aligos is eligible for up to $420M in potential clinical, regulatory, & sales milestones plus tiered high single-digit royalties on net sales in licensed territories.
  • Aligos retains all development & commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, & other global markets.
  • The Breakthrough Therapy Designation makes pevifoscorvir sodium eligible for priority review of a New Drug Application in China.
  • Aligos & Amoytop have formed a joint steering committee to oversee the collaboration.
  • Aligos plans to enter its antisense oligonucleotide ALG-170675 into clinical trials in China during the third quarter of 2026.